About Rexer Pharma
Rexer Pharma is a company based in Hyderabad (India) founded in 1996. It operates as a B2B and Export. The company has 16 employees. Rexer Pharma offers products and services including Ampirex 250, Ciprex-250, Diclorex, Hazer-20, and Recobal. Rexer Pharma operates in a competitive market with competitors including Unither, Akums, Jubilant Life Sciences, Recipharm and CoreRx, among others.
- Headquarter Hyderabad, India
- Employees 16
- SectorsHealthcare
- Email••••••••
- Website rexerpharma.com
- Legal Name Rexer Pharma Private Limited
- Date of Incorporation 20 Dec, 1996
- Jurisdiction Hyderabad, Telangana, India
- Annual Revenue₹2.90 Cr
FY 2024 · +5% YoY
- Net Profit₹73,139
FY 2024 · 0% margin
- EBITDA₹5.3 Lakh
FY 2024 · 2% margin
- Employee Count16
Associated legal entities of Rexer Pharma
Rexer Pharma operates through Rexer Pharma Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2024) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Rexer Pharma Private Limited CIN U24230TG1996PTC026005 | Active | 20 Dec 1996 | Hyderabad, Telangana | ₹2.9 Cr | 16 | 3 | View details |
Products & Services of Rexer Pharma
Rexer Pharma offers a comprehensive portfolio of products and services, including Ampirex 250, Ciprex-250, Diclorex, Hazer-20, and Recobal.
Antibiotic formulation for treating bacterial infections effectively.
Antibiotic drug used for infection control and prevention.
Anti-inflammatory medication for pain relief and inflammation reduction.
Drug for gastrointestinal issues and symptom management.
Supplement for nerve health and rejuvenation support.
Board of directors of Rexer Pharma Private Limited (Rexer Pharma)
Rexer Pharma Private Limited is the primary company behind Rexer Pharma. The board of Rexer Pharma Private Limited currently have 3 directors; the longest-serving is Madallapalli Surya Mohan, appointed in 1996. 1 earlier director has ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Madallapalli Surya Mohan DIN 01880096 | Director | 20 Dec 1996 | 29 yrs 9 mo | Rexer Pharma Private Limited |
| Raghava Reddy Gureddygari DIN 02417480 | Director | 20 Dec 1996 | 29 yrs 9 mo | Rexer Pharma Private Limited |
| Sujana Seelam DIN 07715153 | Director | 23 Jan 2017 | 9 yrs 8 mo | Rexer Pharma Private Limited |
Financials of Rexer Pharma
Figures of Rexer Pharma Private Limited, the primary company behind Rexer Pharma, for FY 2024. Revenue was ₹2.90 Cr (+5% year on year). Net profit was ₹73,139 (0% margin). EBITDA was ₹5.3 Lakh (2% margin). Revenue has grown at a compounded annual rate of +9% over three years and -1% over five years.
- ₹2.90 CrRevenue · FY 2024 · +5% YoY
- ₹73,139Net profit · 0% margin
- ₹5.3 LakhEBITDA · 2% margin
- ₹40 LakhPaid-up capital
- 16Employees (provident fund records)
- +9%Revenue CAGR, 3 years
- -1%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Rexer Pharma Private Limited are on its company page.
Detailed financial statements for Rexer Pharma
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Competitors of Rexer Pharma
Rexer Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Unither, Akums, Jubilant Life Sciences, Recipharm and CoreRx, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| unither-pharma.com | 1993 | Paris, France | – | – | Contract development and manufacturing organization for proprietary and generic drugs | |
| akums.in | 2004 | Delhi, India | $70M | 395 | CDMO focusing on spectrum of dosage forms and therapeutic segments | |
| jubl.com | 1978 | Noida, India | – | – | Company offering a suite of R&D and manufacturing services for small molecules and generics | |
| recipharm.com | 1995 | Jordbro, Sweden | – | 1,083 | Pharmaceutical development and manufacturing services are offered contractually. | |
| corerxpharma.com | 2006 | Clearwater, United States | $15M | – | CDMO with a focus on early phase drug product development | |
| neclife.com | 1995 | Chandigarh, India | $46.85M | 175 | Cephalosporin APIs and generic formulations are manufactured. | |
| windlas.com | 2001 | Gurugram, India | $12.96M | 1,264 | Biopharma regulatory affairs, quality control, and strategy services are provided. | |
| medpharm.com | 1998 | Guildford, United Kingdom | – | 108 | Topical and inhaled drug delivery formulations are developed and manufactured. |
Detailed competitors of Rexer Pharma
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Similar companies to Rexer Pharma
10 companies that operate in the same segment as Rexer Pharma (Pharmaceuticals & Distribution), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Pharmaceutical products are manufactured and marketed worldwide. | 1891 | Kenilworth, Warwickshire, United Kingdom | – | USD 64.93 B | 781 | |
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | 2014 | New York, New York, United States | USD 1.3 B | USD 8.26 M | 750 | |
Developer of pharmaceutical products for treating multiple diseases | 1980 | Thousand Oaks, California, United States | – | USD 33.23 B | 28,000 | |
Biopharmaceutical research and drug development are conducted globally by AbbVie. | 2012 | Chicago, Illinois, United States | – | USD 61.16 B | 55,000 | |
Traditional pharmaceutical medicines are developed for multiple health fields. | 1876 | United States | – | USD 65.18 B | 47,000 | |
Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others | 1987 | Foster City, California, United States | – | USD 29.45 B | 17,600 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 215.5 M | USD 29.62 M | 225 | |
Developer of medical devices, generic pharmaceuticals, and nutrition products | 1888 | Libertyville, Illinois, United States | – | USD 44.33 B | 3,710 | |
Medicines and health products are retailed through pharmacy outlets. | 2006 | Hyderabad, Telangana, India | USD 268.78 M | USD 734.57 M | 25,010 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Rexer Pharma
Rexer Pharma was founded in 1996.
Rexer Pharma is headquartered in Hyderabad, India. It is registered at Hyderabad, Telangana, India.
Rexer Pharma has 16 employees.
The primary company behind Rexer Pharma, Rexer Pharma Private Limited, reported revenue of ₹2.90 Cr for FY 2024, up 5% year on year.
Rexer Pharma is a pharmaceutical company that produces and exports a wide range of formulations, including antibiotics, anti-inflammatory drugs, and hormonal injectables. They operate through manufacturing processes focused on quality and product development, supplying to global markets. Based in Hyderabad, India, they serve as exporters and suppliers, meeting industry standards for generics and specialty products while emphasizing affordable healthcare solutions.
Rexer Pharma's top competitors include Jubilant Life Sciences, Akums and Nectar Lifesciences.
Rexer Pharma offers Ampirex 250, Ciprex-250, Diclorex, Hazer-20, and Recobal.
Rexer Pharma operates through Rexer Pharma Private Limited.
The legal entities of Rexer Pharma currently have 3 directors, including Sujana Seelam, Madallapalli Surya Mohan, Raghava Reddy Gureddygari.